title: The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice.
abstract: In the present study, we investigated the antidepressive activity of opiorphin with central administration in the forced swim test in mice. Intracerebroventricular (i.c.v.) administration of opiorphin (1-6 μg/mouse) dose-dependently decreased the immobility time, which was reversed by nonselective opioid receptor antagonist naloxone, δ-selective naltrindole and μ-selective β-FNA. The data suggested that central administration of opiorphin produced an antidepressant-like effect by activating both μ and δ opioid receptors indirectly. In order to eliminate the possibility of a false-positive result in the forced swim test, locomotor activity was checked in both non-habituated and habituated mice. Opiorphin had no influence on non-habituated mice, though had weak effect on habituated mice. In addition, mice treated with opiorphin did not display any convulsive behaviors.
authors.affiliation: Institute of Biochemistry and Molecular Biology, School of Life Science, Lanzhou University, 222 Tian Shui South Road, Lanzhou 730000, PR China.
authors.forename: Qing-Zhen
authors.initials: QZ
authors.lastname: Yang
authors.forename: Song-Song
authors.initials: SS
authors.lastname: Lu
authors.forename: Xiao-Zhu
authors.initials: XZ
authors.lastname: Tian
authors.forename: Ai-Min
authors.initials: AM
authors.lastname: Yang
authors.forename: Wan-Wen
authors.initials: WW
authors.lastname: Ge
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006185:Habituation, Psychophysiologic; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000502:physiology*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors / Q000502:physiology*; D012471:Salivary Proteins and Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction
chemical_list: D000928:Antidepressive Agents; D009842:Oligopeptides; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D012471:Salivary Proteins and Peptides; C517879:glutaminyl-arginyl-phenylalanyl-seryl-arginine; D009270:Naloxone; D009271:Naltrexone; C024524:beta-funaltrexamine